| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.07 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.055 | 0.07 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.07 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |